Answers are grounded in this paper and cite their sources.
Preclinical evaluation reveals potent anticonvulsant activity for 4-methyl-3-phenoxypyridine 1-oxide in animal models, suggesting a phenytoin-like profile limited by rapid metabolic clearance.
The anticonvulsant activity of a series of 3-phenoxypyridine 1-oxides is described. An investigation carried out to optimize the activity/side effect ratio provided 4-methyl-3-phenoxypyridine 1-oxide, 3, as the derivative of choice. Overall, 3 has a pharmacological profile that is very similar to phenytoin. It exhibited significant anticonvulsant activity at doses that did not produce ataxia or sedation but caused increased spontaneous behavioral activity not seen with most anticonvulsants. The short duration of pharmacological effect of 3 was attributed to metabolic hydroxylation at the C-4 pyridine methyl group; however, structural modifications designed to inhibit this metabolic pathway were unsuccessful.
No takes yet. Share an insight, caveat, or question.
Pavia et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: